Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Psychopharmacology

• Publication date

  1996-04-01

• Fields of study

  Biology, Medicine, Psychology

• Identifiers
  DOI 10.1007/BF02247441PMID 8739551
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice

  2005cited by this paper
• The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze

  2005cited by this paper
• Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze

  2005cited by this paper
• Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience

  2005cited by this paper
• The use of a plus-maze to measure anxiety in the mouse

  2004cited by this paper
• Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment

  2004cited by this paper
• Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze.

  1995cited by this paper
• Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety.

  1995cited by this paper
• Anxiolytic-like effects of yohimbine in the murine plus-maze: strain independence and evidence against α2-adrenoceptor mediation

  1995cited by this paper
• Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs

  1995cited by this paper
• Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze.

  1995cited by this paper
• Cholecystokinin and anxiety: promises and pitfalls.

  1995cited by this paper
• Cholecystokinin and anxiety: promises and pitfalls.

  1995cited by this paper
• Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test.

  1994cited by this paper
• Biological actions of cholecystokinin.

  1994cited by this paper
• Effects of BOC-CCK-4 and L 365.260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze.

  1994cited by this paper
• Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.

  1994cited by this paper
• Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients

  1994cited by this paper
• Heterogeneity of CCK-B receptors involved in animal models of anxiety.

  1994cited by this paper
• Placebo-controlled study of a CCKB antagonist in patients with panic disorder

  1994cited by this paper
• Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan.

  1994cited by this paper
• Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.

  1994cited by this paper
• Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats

  1994cited by this paper
• Dopamine D1 and D2 receptor ligands modulate the behaviour of mice in the elevated plus-maze.

  1994cited by this paper
• Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol

  1994cited by this paper
• Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety

  1994cited by this paper
• The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.

  1994cited by this paper
• Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety.

  1994cited by this paper
• The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze.

  1994cited by this paper
• CCK in animal and human research on anxiety.

  1993cited by this paper
• Brief Presentation of the Story and Present Status of Studies of the Vertebrate Cholinergic System

  1993cited by this paper
• Social isolation of rats increases the density of cholecystokinin receptors in the frontal cortex and abolishes the anti-exploratory effect of caerulein

  1993cited by this paper
• Anxiety enhancement in the murine elevated plus maze by immediate prior exposure to social stressors.

  1993cited by this paper
• Failure of intravenous pentagastrin challenge to induce panic-like effects in rhesus monkeys.

  1993cited by this paper
• Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety.

  1993cited by this paper
• Lasting effects on rodent anxiety of a single exposure to a cat.

  1993cited by this paper
• Anxiogenic stimuli in the elevated plus-maze.

  1993cited by this paper
• Involvement of D2 dopaminergic receptors in the emotional and motivational responses induced by injection of CCK-8 in the posterior part of the rat nucleus accumbens.

  1993cited by this paper
• EFFECTS OF CHOLECYSTOKININ TETRAPEPTIDE (CCK-4) AND THE CCKB ANTAGONIST LY-288513 IN A PUTATIVE MODEL OF PANIC IN THE MOUSE

  1993cited by this paper
• An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16–6028) in the murine elevated plus‐maze

  1993cited by this paper
• [Study of induced effects by selective CCKB agonists cholecystokinin in the nociception and behavior in rodents].

  1992cited by this paper
• Anxiogenic‐like effects of fluprazine and eltoprazine in the mouse elevated plus‐maze: profile comparisons with 8‐OH-DPAT, CGS 12066B, TFMPP and mCPP1

  1992cited by this paper
• Ethological analysis of the role of CCK in anxiety

  1992cited by this paper
• Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III)

  1992cited by this paper
• The cholecystokinin hypothesis of panic and anxiety disorders: a review

  1992cited by this paper
• Anxiolytic effects of CCK-B antagonists.

  1991cited by this paper
• 'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice.

  1991cited by this paper
• Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behaviour?

  1991cited by this paper
• The behavioural properties of CI‐988, a selective cholecystokininB receptor antagonist

  1991cited by this paper
• Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.

  1991cited by this paper
• Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.

  1991cited by this paper
• Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat.

  1991cited by this paper
• Cholecystokinin and anxiety.

  1990cited by this paper
• EVIDENCE THAT THE ANXIOLYTIC-LIKE EFFECTS OF THE CCK ANTAGONISTS DEVAZEPIDE AND L-365,260 IN THE ELEVATED PLUS-MAZE PARADIGM IN RATS ARE MEDIATED BY CCK RECEPTORS

  1990cited by this paper
• Cholecystokinin-Tetrapeptide Induces Panic Attacks in Patients with Panic Disorder *

  1990cited by this paper
• Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.

  1990cited by this paper
• Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

  1989cited by this paper
• Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

  1989cited by this paper
• Two brain cholecystokinin receptors: implications for behavioral actions.

  1986cited by this paper
• Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat.

  1985cited by this paper
• Determination of cholecystokinin tetrapeptide and cholecystokinin octapeptide sulfate in different rat brain regions by high-pressure liquid chromatography with electrochemical detection.

  1983cited by this paper
• Characterization of Receptors for Cholecystokinin and Related Peptides in Mouse Cerebral Cortex

  1981cited by this paper
• Cholecystokinin receptor binding in brain and pancreas: regulation of pancreatic binding by cyclic and acyclic guanine nucleotides.

  1980cited by this paper
• Interaction of cholecystokinin with specific membrane receptors on pancreatic acinar cells.

  1980cited by this paper
• Demonstration of a putative receptor site for cholecystokinin in rat brain

  1980cited by this paper
• Cholecystokinin receptor binding in brain and pancreas: Regulation of pancreatic bindign by cyclic and acyclic guanine nucleotides

  1980cited by this paper
• New peptide in the vertebrate CNS reacting with antigastrin antibodies

  1975cited by this paper
• Cholecystokinin and pancreozymin, one single hormone?

  1966cited by this paper
• A HORMONE MECHANISM FOR GALL-BLADDER CONTRACTION AND EVACUATION

  1928cited by this paper

• Anxiolytic- and antidepressant-like activities of hydroethanol leaf extract of Newbouldia laevis (P.Beauv.) Seem. (Bignoniaceae) in mice.

  2019cites this paper
• Enhanced activity of pyramidal neurons in the infralimbic cortex drives anxiety behavior

  2019cites this paper
• Central apelin administration and restraint stress induce hypothalamic cholecystokinin release via the APJ receptor

  2018cites this paper
• Loss of Lypd6 leads to reduced anxiety‐like behaviour and enhanced responses to nicotine

  2017cites this paper
• Infralimbic Endothelin1 Is Critical for the Modulation of Anxiety-Like Behaviors

  2016cites this paper
• Interaction between the Cholecystokinin and Endogenous Cannabinoid Systems in Cued Fear Expression and Extinction Retention

  2015cites this paper
• Amygdala NRG1–ErbB4 Is Critical for the Modulation of Anxiety-Like Behaviors

  2015cites this paper
• Evaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autism

  2015influential citation
• Concurrent maternal and pup postnatal tobacco smoke exposure in Wistar rats changes food preference and dopaminergic reward system parameters in the adult male offspring.

  2015cites this paper
• Anxiety-like, novelty-seeking and memory/learning behavioral traits in male Wistar rats submitted to early weaning.

  2014cites this paper
• ANXIOLYTIC EFFECT OF MEDICAGO SATIVA SEEDS EXTRACT ON RODENTS

  2014cites this paper
• Enhanced excitability in the infralimbic cortex produces anxiety-like behaviors.

  2013influential citation
• BETA 2 NICOTINIC ACETYLCHOLINE RECEPTOR CONTRIBUTIONS TO ANXIETY-LIKE BEHAVIOR

  2013cites this paper
• Antiulcer and Anxiolytic Effect of Durenta repens Linn in Experimental Animal Model

  2013cites this paper
• Antidepressant activity of ethanolic extract of leaves of Centella asiatica . Linn by In vivo methods.

  2012cites this paper
• Low Dose Nicotine and Antagonism of β2 Subunit Containing Nicotinic Acetylcholine Receptors Have Similar Effects on Affective Behavior in Mice

  2012cites this paper
• Role of the Cholecystokinin System in Anxiolytic Activity of Dipeptide GB-115

  2012cites this paper
• NEURONAL NETWORK OF PANIC DISORDER: THE ROLE OF THE NEUROPEPTIDE CHOLECYSTOKININ

  2012cites this paper
• Maternal prolactin inhibition at the end of lactation affects learning/memory and anxiety-like behaviors but not novelty-seeking in adult rat progeny.

  2011cites this paper
• Comparison of self-administration behavior and responsiveness to drug-paired cues in rats running an alley for intravenous heroin and cocaine

  2010cites this paper
• Anxiolytic and sedative effects of Byrsocarpus coccineus Schum. and Thonn. (Connaraceae) extract

  2010cites this paper
• Effekte der systemischen Cholecystokiningabe bei C57BL/6-Mäusen und Einfluss einer chronischen Vitamin D- und /oder Paroxetinbehandlung auf das Verhalten und die HPA-Ahcse bei C57BL/6- und DBA/2-Mäusen

  2009cites this paper
• Functional Interactions between Endocannabinoid and CCK Neurotransmitter Systems May Be Critical for Extinction Learning

  2009cites this paper
• GABA and Histamine Interaction in the Basolateral Amygdala of Rats in the Plus-Maze Test of Anxiety-Like Behaviors

  2008cites this paper
• Anti-depressant and anti-nociceptive effects of 1,4-benzodiazepine-2-ones based cholecystokinin (CCK(2)) antagonists.

  2007cites this paper
• The myth of panic spontaneity: Consideration of behavioral and neurochemical sensitization.

  2007cites this paper
• CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies

  2006cites this paper
• Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse.

  2006cites this paper
• Light/dark cycle manipulation influences mice behaviour in the elevated plus maze.

  2006cites this paper
• Cholecystokinin2 receptor deficient mice: changes in function of GABA-ergic system

  2005cites this paper
• Facteurs de variabilité de l'effet de substances anxiolytiques sur le labyrinthe en croix surélevé chez la Souris

  2005cites this paper
• Cholecystokinin and GABA interaction in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety.

  2005cites this paper
• Systemic and intra-dorsal periaqueductal gray injections of cholecystokinin sulfated octapeptide (CCK-8s) induce a panic-like response in rats submitted to the elevated T-maze.

  2004cites this paper
• Central D-Ala2-Met5-enkephalinamide mu/delta-opioid receptor activation reverses the anxiogenic-like properties of cholecystokinin on locomotor and rearing activity in CD-1 mice.

  2003cites this paper
• Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models.

  2003cites this paper
• Central d-Ala2-Met5-enkephalinamide μ/δ-opioid receptor activation reverses the anxiogenic-like properties of cholecystokinin on locomotor and rearing activity in CD-1 mice

  2003cites this paper
• Spatial memory deficit and emotional abnormality in OLETF rats.

  2002cites this paper
• Absence of anxiolytic response to chlordiazepoxide in two common background strains exposed to the elevated plus‐maze: importance and implications of behavioural baseline

  2002cites this paper
• The experimental pharmacotherapy of benzodiazepine withdrawal.

  2002cites this paper
• Synthesis and evaluation of N1‐substituted‐3‐propyl‐1,4‐benzodiazepine‐2‐ones as cholecystokinin (CCK2) receptor ligands

  2002cites this paper
• Anxiety-related behaviors in cholecystokinin-A, B, and AB receptor gene knockout mice in the plus-maze.

  2002cites this paper
• Acute exposure to a low or mild dose of soman: biochemical, behavioral and histopathological effects.

  2001cites this paper
• Anxiolytic effects of valproate and diazepam in mice are differentially sensitive to picrotoxin antagonism.

  2001cites this paper
• Increased anxiety behavior in OLETF rats without cholecystokinin-A receptor.

  2000cites this paper
• Behavioral effects of diazepam in the murine plus-maze: flumazenil antagonism of enhanced head dipping but not the disinhibition of open-arm avoidance.

  1999cites this paper
• Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?

  1999cites this paper
• Behaviorally selective effects of neuroactive steroids on plus-maze anxiety in mice.

  1998cites this paper
• Cholecystokinin B receptors in the periaqueductal gray potentiate defensive rage behavior elicited from the medial hypothalamus of the cat.

  1998cites this paper
• Effects of cholecystokinin-receptor agonists on cortical 5-HT release in guinea pigs on the X-maze.

  1998cites this paper
• CCK in anxiety and cognitive processes.

  1998cites this paper
• CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity.

  1998cites this paper
• Comparative effects of novel 5-HT1A receptor ligands, LY293284, LY315712 and LY297996, on plus-maze anxiety in mice

  1998cites this paper
• Dopamine D4 receptor and anxiety: behavioural profiles of clozapine, L-745,870 and L-741,742 in the mouse plus-maze.

  1997cites this paper
• Animal models of 'anxiety': where next?

  1997cites this paper
• Pharmacological evaluation of IQM‐95,333, a highly selective CCKA receptor antagonist with anxiolytic‐like activity in animal models

  1997cites this paper
• Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine. II. The elevated plus-maze.

  1997cites this paper
• Animal models of anxiety: an ethological perspective.

  1997cites this paper
• The effect of drugs acting on CCK receptors and rat free exploration in the exploration box.

  1997cites this paper
• CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours

  1997cites this paper
• Anxiety, defence and the elevated plus-maze.

  1997cites this paper
• Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze.

  1997cites this paper
• Different behavioural profiles of the R(+)- and S(-)-enantiomers of 8-hydroxy-2-(di-n-propylamino) tetralin in the murine elevated plus-maze.

  1996cites this paper
• GABAergic influences on plus-maze behaviour in mice

  1996cites this paper